Mendus, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, and NorthX Biologics, a contract development and manufacturing organization that serves as the National Swedish Innovation Hub for the good manufacturing practice (GMP) manufacture of biologics used in vaccines, gene therapies, and other advanced medicinal products, announced a manufacturing alliance on June 8, 2023. The companies will co-establish cell therapy manufacturing capabilities in Sweden for use in late-stage development and commercial manufacturing of Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine.
